• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Epigenetics Drugs And Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018 Product Image

Epigenetics Drugs And Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

  • Published: June 2013
  • Region: Global
  • 112 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • 4SC AG
  • Cellcentric Ltd.
  • Eisai Co. Ltd.
  • Epizyme, Inc.
  • Mdxhealth
  • Novartis International AG
  • MORE

Epigenetics Drugs And Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

The research report on the epigenetics drugs and diagnostic technologies market provides detailed analysis of the global market and helps in understanding the driving forces for the growth of these technologies. The report also provides analysis of the drugs market by the mechanism of its action namely, DNMT inhibitors and HDAC inhibitors. The report also discusses the diagnostic technologies market by types which include DNA methylation and ChIP (Chromatin Immunoprecipitation) technology. Market size estimates and forecasts for the period 2010 to 2018 has been given for each segment and sub-segment, in terms of USD million, using 2010 as the base year.

The market has also been segmented geographically into four regions namely North America, Europe, Asia-Pacific, and Rest of the World (RoW). Market size and forecast has been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the epigenetics market and future opportunities are provided in the report.

Competitive READ MORE >

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Epigenetics Market (2011 & 2018)
2.2 Global Epigenetics Market, by Segments, 2011 (USD Million)

Chapter 3 Market Overview
3.1 Introduction
3.2 Market Drivers
3.2.1 Increase in Demand for the Treatment of Oncology and Non-Oncology Conditions
3.2.2 Huge Amounts of Investment
3.2.3 Advances in Screening Tools
3.2.4 Impact Analysis of Market Drivers
3.3 Market Restraints
3.3.1 Genericization of Major Drugs
3.3.2 Impact Analysis of Market Restraints
3.4 Market Opportunities
3.5 Porter's Five Forces Analysis
3.5.1 Bargaining Power of Buyers
3.5.2 Bargaining Power of Suppliers
3.5.3 Threat of New Entrants
3.5.4 Threat of Substitutes
3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis

Chapter 4 Epigenetics Drugs Market, By Mechanism Of Action
4.1 Overview
4.1.1 Global Epigenetic Drugs Market, By Mechanism Of Action, 2010 – 2018 (USD Million)
4.1.2 Histone Deacetylase (HDAC) Inhibitors
4.1.3 Global HDAC Inhibitors Market, By Drugs, 2010 – 2018 (USD Million)
4.1.3.1 Vorinostat
4.1.3.2 Global Vorinostat Market, By Types 2010 – 2018 (USD Million)
4.1.3.3 Romidepsin
4.1.3.4 Global Romidepsin Market, By Types 2010 – 2018 (USD Million)
4.1.4 DNA Methyltransferase (DNMT) Inhibitors
4.1.5 Global DNMT Inhibitors Market, By Drugs, 2010–2018 (USD Million)
4.1.5.1 Decitabine
4.1.5.2 Global Decitabine Market, By Types 2010 – 2018 (USD Million)
4.1.5.3 Azacitidine
4.1.5.4 Global Azacitidine Market, By Types 2010 – 2018 (USD Million)
4.1.6 Pipeline Drugs
4.1.6.1 Mocetinostat
4.1.6.2 Abexinostat
4.1.6.3 Resminostat
4.1.6.4 Rocilinostat
4.1.6.5 CHR 3996
4.1.6.6 EVP 0334
4.1.6.7 Panobinostat
4.1.6.8 Belinostat
4.1.6.9 Entinostat
4.1.6.10 Valproic Acid
4.1.6.11 Histone Methyltransferase (HMT) Inhibitors

Chapter 5 Epigenetics Diagnostic Technology Market, By Types
5.1 Overview
5.1.1 Global Epigenetic Diagnostic Technologies Market, By Types, 2010 – 2018 (USD Million)
5.2 DNA Methylation
5.2.1.1 Global DNA Methylation Technology Market, By Types 2010 – 2018 (USD Million)
5.2.2 Chromatin Immunoprecipitation (Chip)
5.2.2.1 Global Chromatin Immunoprecipitation (Chip) Technology Market, By Types 2010 – 2018 (USD Million)

Chapter 6 Global Epigenetics Technologies Market, By Geography
6.1 Overview
6.1.1 Global Epigenetics Technologies Market, By Geography, 2010–2018 (USD Million)
6.2 Comparative Analysis: Epigenetic Technologies Market, By Geography, 2011 & 2018 (Value %)
6.3 North America
6.3.1 North America Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
6.4 Europe
6.4.1 Europe Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
6.5 Asia-Pacific
6.5.1 Asia-Pacific Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
6.6 Rest of the World
6.6.1 Row Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)

Chapter 7 Competitive Landscape
7.1 Market Share Analysis, By Key Players (%)

Chapter 8 Recommendations
8.1 Market Strategy for Success
8.2 Barriers to be Considered

Chapter 9 Company Profiles
9.1 4SC AG
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Product Overview
9.1.4 Business Strategy
9.1.5 Recent Developments
9.2 Acetylon Pharmaceuticals, Inc.
9.2.1 Company Overview
9.2.2 Financial Overview
9.2.3 Product Overview
9.2.4 Business Strategy
9.2.5 Recent Developments
9.3 Astex Pharmaceuticals Inc.
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Product Portfolio
9.3.4 Business Strategy
9.3.5 Recent Developments
9.4 Cellcentric Ltd.
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Product Portfolio
9.4.4 Business Strategy
9.4.5 Recent Developments
9.5 Celleron Therapeutics Ltd.
9.5.1 Company Overview
9.5.2 Financial Overview
9.5.3 Product Portfolio
9.5.4 Business Strategy
9.6 Celgene Corporation
9.6.1 Business Overview
9.6.2 Financial Overview
9.6.3 Business Strategy
9.6.4 Recent Developments
9.7 Chroma Therapeutics Ltd.
9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Product Overview
9.7.4 Business Strategy
9.7.5 Recent Developments
9.8 Epigentek Group Inc.
9.8.1 Business Overview
9.8.2 Financial Overview
9.8.3 Business Strategy
9.8.4 Recent Developments
9.9 Eisai Co. Ltd.
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Product Portfolio
9.9.4 Business Strategy
9.9.5 Recent Developments
9.10 Envivo Pharmaceuticals Inc.
9.10.1 Company Overview
9.10.2 Financial Overview
9.10.3 Product Portfolio
9.10.4 Business Strategy
9.11 Epizyme, Inc.
9.11.1 Company Overview
9.11.2 Financial Overview
9.11.3 Product Portfolio
9.11.4 Business Strategy
9.11.5 Recent Developments
9.12 Illumina Inc.
9.12.1 Company Overview
9.12.2 Financial Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies
9.12.5 Recent Developments
9.13 Mdxhealth
9.13.1 Company Overview
9.13.2 Financial Overview
9.13.3 Product Portfolio
9.13.4 Business Strategy
9.13.5 Recent Developments
9.14 Merck & Company Inc.
9.14.1 Company Overview
9.14.2 Financial Overview
9.14.3 Product Portfolio
9.14.4 Business Strategy
9.15 Novartis International AG
9.15.1 Company Overview
9.15.2 Financial Overview
9.15.3 Product Portfolio
9.15.4 Business Strategy
9.15.5 Mergers And Acquisitions
9.16 Oncolys Biopharma Inc.
9.16.1 Company Overview
9.16.2 Financial Overview
9.16.3 Product Portfolio
9.16.4 Business Strategy
9.17 Pharmacyclics, Inc.
9.17.1 Company Overview
9.17.2 Financial Overview
9.17.3 Product Portfolio
9.17.4 Business Strategy
9.17.5 Recent Developments
9.18 Pharmacyclics, Inc.
9.18.1 Company Overview
9.18.2 Financial Overview
9.18.3 Product Portfolio
9.18.4 Business Strategy
9.18.5 Recent Developments
9.19 Repligen Corporation
9.19.1 Company Overview
9.19.2 Financial Overview
9.19.3 Product Portfolio
9.19.4 Business Strategy
9.19.5 Recent Developments
9.20 Spectrum Pharmaceuticals
9.20.1 Company Overview
9.20.2 Financial Overview
9.20.3 Product Portfolio
9.20.4 Business Strategy
9.20.5 Recent Developments
9.21 Syndax Pharmaceuticals, Inc.
9.21.1 Company Overview
9.21.2 Financial Overview
9.21.3 Product Portfolio
9.21.4 Business Strategy
9.21.5 Recent Developments
9.22 Topotarget A/S
9.22.1 Company Overview
9.22.2 Financial Overview
9.22.3 Product Portfolio
9.22.4 Business Strategy
9.22.5 Recent Developments
9.23 Valirx Plc
9.23.1 Company Profile
9.23.2 Financial Overview
9.23.3 Product Portfolio And Technology
9.23.4 Business Strategy
9.23.5 Recent Developments
List of Figures

FIG. 1 Epigenetics Technologies: Market Segmentation
FIG. 2 Global Epigenetics Market, By Segments, 2011 (USD Million)
FIG. 3 Evolution in Epigenetics
FIG. 4 Porter's Five Forces Analysis: Global Epigenetics Drugs and Diagnostic Technologies Market
FIG. 5 Market Attractiveness Analysis: Global Epigenetics Technologies Market, by Geography
FIG. 6 Global Vorinostat Market, 2010 – 2018 (USD Million)
FIG. 7 Global Romidepsin Market, 2010 – 2018 (USD Million)
FIG. 8 Global Decitabine Market, 2010 – 2018 (USD Million)
FIG. 9 Global Azacitidine Market, 2010 – 2018 (USD Million)
FIG. 10 Global DNA Methylation Technology Market, 2010 – 2018 (USD Million)
FIG. 11 Global Chromatin Immunoprecipitation (Chip) Technology Market, 2010 – 2018 (USD Million)
FIG. 12 Comparative Analysis: Epigenetic Technologies Market, By Geography, 2011 & 2018 (Value %)
FIG. 13 Epigenetics Drugs: Market Share, by Key Players, 2011 (%)
FIG. 14 Epigenetics Diagnostics Technologies: Market Share, by Key Players, 2011 (%)
FIG. 15 4SC AG, Annual Revenues: 2010 – 2012 (USD Million)
FIG. 16 Astex Pharmaceuticals, Annual Revenues: 2010 – 2012 (USD Million)
FIG. 17 Celgene Corporation: Annual Revenues, 2010 – 2012 (USD Million)
FIG. 18 Eisai Pharmaceuticals, Annual Revenues: 2010 – 2012 (1 Yen=1.215 USD) (USD Billion)
FIG. 19 Illumina Inc., Annual Sales: 2010 – 2012 (USD Million)
FIG. 20 Mdxhealth, Annual Revenues: 2010 – 2012 (1 Euro = 1.32 USD) (USD Million)
FIG. 21 Merck & Co. Inc., Annual Sales: 2010 – 2012 (USD Billion)
FIG. 22 Novartis International AG., Annual Sales: 2010 – 2012 (USD Million)
FIG. 23 Pharmacyclics, Annual Revenues: 2010 – 2012 (USD Million)
FIG. 24 Repligen, Annual Revenues: 2010 – 2012 (USD Million)
FIG. 25 Spectrum Pharmaceuticals, Annual Revenues: 2010 – 2012 (USD Million)
FIG. 26 Topotarget, Annual Revenues: 2010 – 2012 (1 DKK = 0.175 USD) (USD Million)
FIG. 27 Valirx, Annual Revenues: 2010 – 2012 (1 British Pound = 1.59 USD) (USD Million)
List of Tables

TABLE 1 Market Snapshot: Global Epigenetics Market (2011 & 2018)
TABLE 2 Impact Analysis of Market Drivers
TABLE 3 Impact Analysis of Market Restraints
TABLE 4 Global Epigenetic Drugs Market, By Mechanism of Action, 2010 – 2018 (USD Million)
TABLE 5 Global HDAC Inhibitors Market, By Drugs, 2010 – 2018 (USD Million)
TABLE 6 Global DNMT Inhibitors Market, By Drugs, 2010 – 2018 (USD Million)
TABLE 7 Global Epigenetic Diagnostic Technologies Market, By Types, 2010 – 2018 (USD Million)
TABLE 8 Global Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
TABLE 9 North America Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
TABLE 10 Europe Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
TABLE 11 Asia-Pacific Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
TABLE 12 Row Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)

- Epigentek Group Inc.

- 4SC AG

- Acetylon Pharmaceuticals, Inc.

- Astex Pharmaceuticals Inc.

- Celgene Corporation

- Cellcentric Ltd.

- Celleron Therapeutics Ltd.

- Chroma Therapeutics Ltd.

- Eisai Co. Ltd.

- Envivo Pharmaceuticals Inc.

- Epizyme, Inc.

- Illumina Inc.

- Mdxhealth

- Merck & Company Inc.

- Novartis International AG

- Oncolys Biopharma Inc.

- Pharmacyclics, Inc.

- Repligen Corporation

- Spectrum Pharmaceuticals

- Syndax Pharmaceuticals, Inc.

- Topotarget A/S

- Valirx Plc

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos